Method of treating amd in patients refractory to anti-vegf therapy

Abstract

Disclosed herein are methods for the treatment of a patient having an ocular conditions such as age-related macular degeneration or diabetic macular edema through administration of a recombinant binding protein comprising an ankyrin repeat domain. In some embodiments, the composition may be administered every 8 weeks to every 16 weeks. In some embodiments, the patient being treated may be refractory to existing anti-VEGF therapies.

1 . A method of treating age-related macular degeneration, the method comprising the step of administering to a patient in need of such treatment, at a frequency of 12 weeks, a dose of about 2 mg of a recombinant binding protein comprising SEQ ID NO: 3, wherein said patient was refractory to ranibizumab or bevacizumab therapy. 
     
     
         2 . The method of  claim 1 , wherein the binding protein further comprises a polyethylene glycol moiety of at least 5 kDa molecular weight. 
     
     
         3 .- 6 . (canceled) 
     
     
         7 . The method of  claim 2  wherein the binding protein comprises an ankyrin repeat domain conjugated at its C-terminus via a peptide bond to a polypeptide linker and a C-terminal Cys residue, wherein the thiol of the C-terminal Cys is further conjugated to a maleimide-coupled polyethylene glycol. 
     
     
         8 .- 9 . (canceled) 
     
     
         10 . The method of  claim 7 , wherein the polyethylene glycol moiety has a molecular weight of around 20 kDa. 
     
     
         11 . (canceled) 
     
     
         12 . The method of  claim 7 , wherein the maleimide-coupled polyethylene glycol is α-[3-(3-maleimido-1-oxopropyl)amino]propyl-ω-methoxy-polyoxyethylene, and wherein the polyethylene glycol moiety has a molecular weight of at least 10 kDa. 
     
     
         13 .- 19 . (canceled) 
     
     
         20 . The method of  claim 1 , wherein the patient has less than a 20% decrease in the center 1 mm 2  area of the macula after 3 intravitreal injections of ranibizumab, bevacizumab, aflibercept or pegaptanib. 
     
     
         21 - 30 . (canceled)